<DOC>
	<DOCNO>NCT00026442</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Randomized phase II trial compare effectiveness two different dos capecitabine treat woman advance metastatic breast cancer .</brief_summary>
	<brief_title>Capecitabine Treating Women With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare objective response rate woman advance metastatic breast cancer treat two dose level capecitabine . - Compare duration response , time progression , time treatment failure , survival , incidence adverse event , time onset adverse experience patient treat drug . - Compare quality life patient treated drug . OUTLINE : This randomize , multicenter study . Patients stratify accord Karnofsky performance status ( 70-80 % vs 90-100 % ) presence hepatic metastasis ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients receive lower-dose oral capecitabine twice daily day 1-14 . - Arm II : Patients receive higher-dose oral capecitabine twice daily day 1-14 . In arm , course repeat every 21 day absence disease progression unacceptable toxicity . Quality life assess baseline , end third sixth course , completion therapy . PROJECTED ACCRUAL : A total 120 patient ( 60 per treatment arm ) accrue study within 9 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically and/or cytologically confirm breast cancer Advanced and/or metastatic disease At least 1 measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN ( 5 time ULN liver metastasis present ) Alkaline phosphatase great 2.5 time ULN ( 5 time ULN liver metastases present OR 10 time ULN bone metastases present ) No hepatitis Renal : Creatinine great 1.5 time ULN Creatinine clearance least 50 mL/min Cardiovascular : No clinically significant cardiac disease No congestive heart failure No symptomatic coronary artery disease No cardiac arrhythmias poorly control medication No myocardial infarction within past 12 month even adequately control medication Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No severe pain inadequately control analgesic No prior severe unexpected reaction fluoropyrimidine therapy No known hypersensitivity fluorouracil No impair physical integrity upper gastrointestinal tract No malabsorption syndrome No inability swallow tablets No history uncontrolled seizure , central nervous system disorder , psychiatric disability would preclude study participation No serious uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 2 3 prior chemotherapy regimen At least 1 prior chemotherapy regimen contain paclitaxel anthracycline adjuvant therapy advance and/or metastatic disease Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy target lesion unless evidence new disease within irradiated field No concurrent radiotherapy Surgery : No prior organ allograft Other : At least 4 week since prior investigational drug No concurrent enrollment investigational study No concurrent anticancer agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>